Prasterone for the treatment of systemic lupus erythematosus
Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 392
- Referral date:
- 01 October 2000
- Topic area
- Musculoskeletal, Therapeutic procedures
Provisional Schedule
- 1st appraisal committee meeting::
- TBC
- 2nd appraisal committee meeting::
- TBC
Project Team
- Assessment Group / Evidence Review Group:
- TBC
- Communications manager:
- Fraser Woodward
- Executive Lead:
- TBC
- Project manager:
- TBC
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 November 2022 | Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 November 2022 | Discontinued. Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual